NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital bolsters its leadership team with the appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent
Highly experienced partners bringing 25+ years of leadership across top-tierlife-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio development With leadership experience at Blackstone Life Sciences (Deputy Chief Operating...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 (CLDN1) ADCs in solid tumors
Building on its co-lead investments in Alentis Therapeutics’ Series B (2021) and Series C (2023)...
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
This new financing will support broad late-stage clinical development program for visugromab,...
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion
This acquisition reflects the significant clinical progress achieved with Restoret™,EyeBio’s novel...
Jeito Capital announces acquisition of portfolio company HI-Bio™ by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 billion; Biogen to strengthen portfolio to help patients with severe immune-mediated disease
Biogen Inc. (Nasdaq: BIIB) to acquire HI-Bio™ for a total consideration of up to $1.8 billion...
EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting
Twelve week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients...
Jeito Capital participates in a $95 Million financing for HI-Bio™, a US-based clinical-stage biopharma company developing targeted therapies for patients with severe immune-mediated diseases
One year after its first investment, this new significant participation in HI-Bio™’s Series B...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.